Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

Collaboration leverages Neomorph’s leading molecular glue discovery platform and Novo Nordisk’s extensive expertise in cardiometabolic and rare diseases Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 26, 2024 /PRNewswire/ — Neomorph, Inc. today announced it…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks